New Zealand markets open in 48 minutes

BIIB Mar 2023 205.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.74000.0000 (0.00%)
As of 11:30AM EST. Market open.
Full screen
Previous close0.7400
Open0.7400
Bid0.0000
Ask4.5000
Strike205.00
Expiry date2023-03-17
Day's range0.7400 - 0.7400
Contract rangeN/A
Volume2
Open interest7
  • Zacks

    Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

    Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.

  • GlobeNewswire

    Lecanemab Receives Priority Review Status in Japan

    TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis

  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.